In 2022, there were around six deaths per 100,000 adults aged 65 to 69 years in Canada due to Alzheimer's disease. This statistic shows the death rate for Alzheimer's disease among adults in Canada in 2022, by age at time of death.

The age-specific mortality rate of alzheimer's disease at all ages in Canada decreased by 0.8 deaths (-5.76 percent) compared to the previous year. In 2023, the age-specific mortality rate thereby reached its lowest value in recent years.

In 2023, there were an estimated 3,463 deaths due to Alzheimer's disease among women in Canada, compared to around 1,768 deaths among men. This statistic displays the number of deaths due to Alzheimer's disease in Canada from 2000 to 2023, by gender.

In 2023, there were 5,231 deaths in Canada due to Alzheimer's disease, a decrease from 5,413 deaths in the previous year. This statistic displays the number of deaths due to Alzheimer's disease in Canada from 2000 to 2023.

The global Alzheimer’s diagnostics and therapeutics market is expected to enjoy a valuation of US$ 6.6 Billion by the end of the year 2023, and further expand at a CAGR of 8.4% to reach a valuation of ~US$ 14.8 Billion by the year 2033. According to a recent study by Future Market Insights, diagnostics is leading the market with a share of about 54.1% in the year 2022, within the global market.

Data Points	Market Insights
Market Value 2022	US$ 6.1 Billion
Market Value 2023	US$ 6.6 Billion
Market Value 2033	US$ 14.8 Billion
CAGR 2023 to 2032	8.4%
Market Share of Top 5 Countries	68.2%
Key Market Players	Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Novartis AG, Zydus Lifesciences Ltd, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., AMillioneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent pharmaceuticals Ltd., Unichem laboratories Ltd., and Lannett Inc.

Report Scope as per Alzheimer’s Diagnostics and Therapeutics Industry Analysis

Attribute	Details
Forecast Period	2012 to 2022
Historical Data Available for	2023 to 2032
Market Analysis	US$ Million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Israel, North Africa, and South Africa
Key Market Segments Covered	Product, Distribution Channel, and Region
Key Companies Profiled	Biogen Inc. AbbVie, Inc. Teva Pharmaceuticals Ltd. Eisai Co. Ltd. Janssen Pharmaceuticals Inc. Novartis AG Zydus Lifesciences Ltd. Sun Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Aurobindo Pharma Ltd. AMillioneal Pharmaceuticals Inc. Macleods Pharmaceuticals Ltd. Viatris Inc. Lupin Ltd. Cipla Ltd. Torrent pharmaceuticals Ltd. Unichem Laboratories Ltd. Lannett Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

In 2022, there were around 51 deaths due to Alzheimer's disease among adults aged 60 to 64 years in Canada. This statistic shows the number of deaths from Alzheimer's disease among adults in Canada in 2022, by age at time of death.

Market Overview:

The Alzheimer's drugs market is projected to reach USD XX million by 2028, at a CAGR of XX% during the forecast period. The growth in this market can be attributed to factors such as the increasing prevalence of Alzheimer's disease, the rising geriatric population, and technological advancements in drug development. The Cholinergic Drugs segment is projected to account for the largest share of the Alzheimer's drugs market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period. The Memantine drug class is projected to grow at a high rate during the forecast period.

Product Definition:

Alzheimer's drugs sales are the sales of medications used to treat Alzheimer's disease. The importance of Alzheimer's drugs sales is that they provide a large source of revenue for pharmaceutical companies, and this revenue is necessary to support the research and development of new treatments for the disease. And, as the prevalence of Alzheimer's disease increases, so does the potential market for these drugs.

Cholinergic:

Cholinergic is a class of drugs that increase the level of the neurotransmitter acetylcholine in the brain. Acetylcholine is a chemical messenger that is important for memory and learning. Cholinergic drugs are used to treat Alzheimer's disease by improving cognitive function. And, while they are not a cure for Alzheimer's disease, they can improve symptoms and slow the progression of the disease.

Memantine:

Memantine is an anti-amnesic drug used to treat Alzheimer's disease. The current formulation of memantine contains a 4-aminobutryl prodrug as its active ingredient and it is sold under the trade name, Namenda in the U.S., Canada, EU countries, and Japan. And, it is approved for the treatment of moderate to severe Alzheimer's disease.

CombinedDrug:

CombinedDrug is a class of drugs that includes both cholinergic and memantine drugs. CombinedDrug is used to treat Alzheimer's disease by improving cognitive function and slowing the progression of the disease. And, while they are not a cure for Alzheimer's disease, they can improve symptoms and slow the progression of the disease.

Application Insights:

Based on application, the market is segmented into hospital pharmacy, retail pharmacy, and online sales. The online sales segment held the largest share of over 60% in 2017. This can be attributed to growing awareness about Alzheimer s disease and increasing internet usage globally. With a rise in prevalence, there is an increase in demand for effective treatment options that can help patients live a normal life span. This factor has led to an increased number of online pharmacies operating across various countries worldwide. The hospital pharmacy segment held the largest share owing to factors such as the presence of a large patient base with respect to this type of healthcare facility.

Regional Analysis:

North America dominated the market in 2018 and is projected to maintain its position over the forecast period. This can be attributed to increasing R&D investments by various companies, rising healthcare expenditure, and growing government initiatives for developing novel drugs for treating Alzheimer s disease. In addition, favorable reimbursement policies are also projected to drive growth during the forecast period.

The Asia Pacific is projected to witness lucrative growth over the coming years owing to a large patient pool that needs treatment options for Alzheimer s disease as well as increasing awareness about these diseases among patients and their families. Moreover, an increase in healthcare expenditure by governments of various countries has resulted in greater funding available for drug development programs targeting AD patients worldwide and this factor is anticipated favorably impact revenue generation from 2019 to 2028 time-frame.

Growth Factors:

• Increasing elderly population: The elderly population is projected to grow at a CAGR of 3.8% from 2016 to 2020, reaching 1.4 billion by 2020. This will create a large pool of patients with Alzheimer’s disease, thereby driving the demand for Alzheimer’s drugs.
• Rising awareness about Alzheimer’s disease: There is an increasing awareness about Alzheimer’s disease among people and healthcare professionals alike, which is likely to drive the demand for these drugs i

In 2020, there were over 250 thousand people in Ontario living with dementia, compared to around 147 thousand people in Quebec. This statistic illustrates the number of people with dementia in Canada in 2020, by province.